Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04881760 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
A Phase 2 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 338
- Enrollment target
- 20
- Study locations
NCT04881760 is a Phase 2 study of Obesity and Overweight that has completed, run by Eli Lilly and Company. The registered enrollment target is 338 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT04881760, a Phase 2 study of Obesity and Overweight, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 338 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3437943
Study Locations (20)
California
- Anaheim Clinical Trials, LLC - Anaheim
- Valley Research - Fresno
- Velocity Clinical Research, Huntington Park - Huntington Park
- Velocity Clinical Research, Huntington Park - Los Angeles
- Southern California Dermatology, Inc. - Santa Ana
- Coastal Metabolic Research Centre - Ventura
- Diablo Clinical Research, Inc. - Walnut Creek
Florida
- East Coast Institute for Research, LLC - Jacksonville
- Suncoast Clinical Research, Inc. - New Port Richey
- Encore Medical Research - Weston - Weston
Arizona
- Perseverance Research Center - Scottsdale
Illinois
- Springfield Diabetes & Endocrine Center - Springfield
Kansas
- Cotton O'Neil Diabetes and Endocrinology Center - Topeka
Louisiana
- Tandem Clinical Research,LLC - Marrero
Missouri
- StudyMetrix Research - City of Saint Peters
New Jersey
- Amici Clinical Research LLC - Raritan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2021-05-20 |
| Est. Completion | 2022-11-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04881760
The ClinicalTrials.gov registry entry for NCT04881760 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 338 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (59% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04881760 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT04881760 about?
NCT04881760 is a clinical study titled "A Study of LY3437943 in Participants Who Have Obesity or Are Overweight". This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.
What is the current status of trial NCT04881760?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 338 participants. The study started on 2021-05-20. Estimated completion is 2022-11-22.
What conditions does trial NCT04881760 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT04881760?
The interventions under investigation include: Placebo (DRUG), LY3437943 (DRUG).
Who is sponsoring clinical trial NCT04881760?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04881760 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.